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Introduction
Arginine is a positively charged, hydrophilic amino acid 
that is often found on the surface of proteins, where it 
participates in ionic interactions with other amino acid 
side chains and forms stabilizing hydrogen bonds with 
both the peptide backbone and amino acid side chains. 
Th  ese characteristics make it a key amino acid in the 
three-dimensional organization of proteins and in the 
interaction with other biological molecules. Hence, post-
translational modiﬁ  cation of arginine can alter the three-
dimensional protein structure and function and poten-
tially expose previously hidden epitopes to the immune 
system. Deimination (citrullination) of arginine side 
chains (peptidylarginine) to form peptidylcitrulline is one 
of many recognized post-translational modiﬁ  cations of 
this amino acid. Th  is post-translational conversion is 
catalyzed by the family of peptidylarginine deiminase 
(PAD) enzymes. Th   e process of protein citrullination plays 
a vital role in normal physiology, in which it is involved in 
the formation of rigid structures such as hair, skin, and 
myelin sheaths [1]. Aberrant citrullination has been 
observed in diseases of the skin and nervous system and 
in inﬂ  ammatory arthritides, of which rheumatoid arthritis 
(RA) is one example [1]. Despite the ubiquity of citrul  li-
nated proteins, the autoantibody response to citrullinated 
proteins is largely restricted to RA [2]. Th  e switch that 
leads to the generation of antibodies to citrullinated pep-
tides and thus loss of immune tolerance to citrullinated 
proteins is likely to involve a complex interplay of indivi-
dual genetic and environmental factors.
Citrullination by human and bacterial 
peptidylarginine deiminases
In humans, a family of ﬁ  ve PAD enzymes (PAD1 to 4 and 
PAD6), encoded by ﬁ  ve genes clustered on chromosome 
1p35-36, has been described [3]. Apart from PAD4, 
which can translocate to the nucleus, PAD enzymes are 
typically found in the cytoplasm of various cell types and 
show a characteristic tissue distribution. Th  e  localization 
and functions of each of the human PAD enzymes are 
summarized in Table 1. Homologous amino acid sequences 
for some or all of these PADs exist in other eukaryotic 
species, such as the mouse, chicken, frog, and bony ﬁ  sh. 
Among prokaryotic species, PAD activity has, to date, been 
described in Porphyromonas gingivalis only [4]. P. gingivalis
is a major pathogen in periodontitis, a disease that (akin to 
RA) is a chronic inﬂ  ammatory dis  order characterized by 
pro-inﬂ  ammatory cytokine production and erosion of bone.
As protein citrullination in the joint is not speciﬁ  c to 
RA [5] and auto  antibodies to citrullinated proteins 
precede the clinical signs of RA [6], it has been proposed 
that oral citrullination of human and bacterial proteins 
by P. gingivalis PAD (PPAD) in an infectious context prior 
to the onset of RA could break tolerance and trigger a 
latent antibody response against citrullinated protein [7]. 
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by human PADs perpetuates the immune response 
through epitope spreading and cross-reactivity, resulting 
in chronic inﬂ  ammatory disease (Figure 1). Citrullination 
by both human and bacterial PAD enzymes may thus 
provide a target for inhibiting the immune response at an 
early stage in the inﬂ  ammatory pathway of RA.
Th  e best-established autoantigens in RA include α-
enolase, ﬁ   brinogen, vimentin, and type II collagen 
(reviewed in [1]) and all are eﬃ   ciently  deiminated  by 
mammalian PADs. In theory, citrullinated peptides from 
these antigens could also be generated by PPAD, although 
this has yet to be demonstrated experimentally. Alpha-
enolase is of particular interest in this respect because it 
is highly conserved among eukaryotes and prokaryotes. 
A sequence of nine amino acids (Asp-Ser-Arg-Gly-Asn-
Pro-Th  r-Val-Glu) spanning the immunodominant epi-
tope on the peptide known as citrullinated enolase 
peptide-1 (CEP-1) is 100% identical to the corresponding 
region in P. gingivalis enolase, and aﬃ   nity-puriﬁ  ed anti-
bodies to CEP-1 react with recombinant enolase 
citrullinated in vitro from both humans and P. gingivalis 
[8], providing an attractive target for molecular mimicry 
between human and bacterial species.
Etiological association between periodontitis and 
rheumatoid arthritis
Th   e rationale for considering both human and P. gingivalis 
PADs in the etiology and pathology of RA is also based 
on epidemiological data suggesting an asso  ciation 
between the two diseases (reviewed in [9]). Periodontitis 
and RA are chronic inﬂ  ammatory disorders characterized 
by erosion of bone and production of pro-inﬂ  ammatory 
cytokines. Th  e reported prevalence of periodontitis is 
highly variable; in one large study of the American 
population, the prevalence was 4.2% [10]. Epidemiological 
studies have shown that RA is more prevalent among 
patients with periodontal disease (3.95%) than in the 
general population (1%) [11]. In addition, patients with 
RA have a higher frequency of advanced periodontal 
disease than the general population [12]. P. gingivalis, 
Treponema denticola, and Tannerella forsythia are some 
of the major Gram-negative bacteria that exist as part of 
a complex bacterial bioﬁ  lm in the gingival crevice and are 
linked to the development and progression of 
periodontitis but can also be found in lower numbers in 
periodontally healthy subjects [13]. Long-term plaque 
accumulation and an interplay of host and bacterial 
factors result in chronic inﬂ  ammation and tissue damage. 
Destruction of the adjacent bone and periodontal 
ligament attachment may eventually lead to tooth loss 
[14].  P. gingivalis antibody levels have been shown to 
correlate with anti-CCP (anti-cyclic citrulli  nated peptide) 
antibody titres [15], making this periodontopathic oral 
bacterium an attractive candidate environmental trigger 
in the development of RA.
Several research groups have reported an increased 
variety and number of oral bacterial DNA and antibodies 
targeting these bacteria in serum and synovial ﬂ  uid of 
patients with RA and other inﬂ  ammatory joint diseases 
compared with controls (non-inﬂ  ammatory  arthritides 
or healthy donors) [15-19]. Oral bacterial DNA could 
Table 1. Localization and function of human peptidylarginine deiminase enzymes
Localization Function Reference
PAD1 Epidermis, hair follicles, arrector pili muscles, and 
sweat glands
Citrullination of fi  laggrin and keratin, facilitating proteolysis and 
crosslinking of the proteins and contributing to skin cornifi  cation. 
Maintains hydration of stratum corneum and epidermis barrier 
function.
Diff  erentiation of hair follicles.
[66-68]
PAD2 Brain astrocytes, sweat glands, arrector pili muscles, 
skeletal muscle, spleen, macrophages, monocytes, 
epidermis, synovial tissue, and synovial fl  uid
Citrullination of myelin basic protein in the brain and spinal cord, 
promoting electrical insulation of myelin sheaths.
Citrullination of vimentin in apoptotic monocytes and macrophages.
[45,46,66,67,69-73]
PAD3 Upper layers of epidermis and hair follicles Citrullination of trichohyalin, contributing to directional hair growth. [66-68]
PAD4 Hematopoietic cells and infl  amed rheumatoid 
synovium
Citrullination of transcriptional coactivator p300 and histones H2A, 
H3, and H4, regulating gene expression by chromatin remodelling.
Citrullination of fi  brin, contributing to chronic infl  ammation in 
rheumatoid arthritis.
P53-dependent citrullination of proteins following DNA damage, 
translocation of histone chaperone nucleophosmin, and p53-
mediated inhibition of tumor cell growth.
[35,44,45,74]
PAD6 Ovary and testis tissue and peripheral blood 
leukocytes
Amino acids known to be conserved in PAD enzymatic activity are 
not conserved in PAD6. Function and enzymatic activity remain 
unclear.
[3,73]
PAD, peptidylarginine deiminase.
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cells. Owing to the stringent growth requirements of live 
oral bacteria, their presence in the joint is unlikely, and no 
viable organisms have been obtained from synovial ﬂ  uid 
[19]. However, these observations need to be interpreted 
with caution since many bacterial antibody assays using 
whole-bacterium lysates are of questionable speciﬁ  city, 
and the same applies to polymerase chain reaction-based 
detection and DNA-DNA hybridization using a complex 
nucleic acid mixture containing an excess of human DNA. 
A number of antibiotics used in the treatment of 
periodontitis, such as tetracyclines and clarithromycin, are 
eﬃ   cacious in the treatment of RA [20-24], although to 
date there has been no direct evidence that this therapeutic 
eﬀ  ect is due to their anti-bacterial activity. For example, 
minocycline has anti-inﬂ   am  matory and anti-apoptotic 
eﬀ  ects that are separate from its anti-bacterial role and 
that are mediated by inhibition of nitric oxide synthase 
[25], matrix metallo  proteinases [26], and caspases [27]. As 
will be discussed below, minocycline and other tetracycline 
derivatives may also be direct inhibitors of human PAD4 
[28] and P. gingivalis arginine-gingipains [29], which are 
potent proteinases and major virulence factors in perio-
dontal disease.
Human peptidylarginine deiminases in disease
In normal physiology, PAD enzymes are involved in 
regulatory processes such as epidermal diﬀ  erentiation, 
maturation of hair follicles, insulation of nerve ﬁ  bers, and 
epigenetic regulation. Aberrant citrullination contributes 
Figure 1. Simplifi  ed model illustrating the hypothesis that Porphyromonas gingivalis-mediated citrullination triggers anti-citrulline 
autoimmunity in rheumatoid arthritis. Citrullination by P. gingivalis peptidylarginine deiminase (PAD) in the infl  ammatory context of periodontitis 
produces bacterial and host-derived citrullinated peptides to which the immune system mounts a humoral immune response with the production 
of peptidylcitrulline antibodies. Infl  ammation-induced citrullination by human PAD enzymes in the gingiva is also possible (dashed arrow). Tissue 
injury and infl  ammation in the joint lead to activation of human PAD enzymes and citrullination of host proteins, such as α-enolase, vimentin, 
fi  brin(ogen), and collagen type II. Peptidylcitrulline antibodies bind citrullinated host and bacterial peptides, which may show molecular mimicry, 
and in genetically susceptible individuals (presence of the certain HLA alleles), intra- and intermolecular epitope spreading leads to a sustained 
immune response with the formation of high-affi   nity antibodies to host citrullinated proteins.
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orders such as multiple sclerosis, Alzheimer disease, and 
prion disease [30-32]. Citrullination of histones and other 
nuclear proteins by PAD4 is involved in transcriptional 
regulation and response to cellular stresses and contri-
butes to the innate immune response through the forma-
tion of neutrophil extracellular traps [33-36]. Recently, 
citrullination of various chemokines has been shown to 
have functional roles in receptor binding and signalling, 
proteolytic cleavage, and extravasation of neutrophils 
[37,38]. Furthermore, citrullination appears to play a role 
in the coagulation system and associated pathways, and 
this is supported by the ﬁ  ndings that in vitro citrullinated 
ﬁ   brinogen shows impaired thrombin-catalyzed ﬁ  brin 
polymerization [39] and in vitro citrullination of anti-
thrombin with PAD4 abolishes its thrombin-inhibitory 
activity [40]. Both citrullinated ﬁ  brin(ogen) and citrulli-
nated antithrombin were detected in patients with 
inﬂ  am  matory arthritis [40,41].
Citrullination is thus a widespread phenomenon in 
normal physiology and inﬂ  ammation, although targeting 
citrullinated proteins for an autoimmune response is 
relatively restricted to RA as shown by the high speciﬁ  city 
of anti-citrullinated peptide antibodies for RA [2]. Th  ere-
fore, it is important to consider which of the deiminases 
are used for generating the antigens that drive this auto-
immunity. On the transcriptional level, various single-
nucleotide polymorphisms in the PADI4 gene have been 
associated with RA in Asian but not in Caucasian popula-
tions (reviewed in [42]). Suzuki and colleagues [43] 
showed that the presence of the disease-associated 
PADI4 haplotype led to a more stable mRNA, which they 
suggested increased PAD4 expression and thus levels of 
citrullinated proteins. However, as PAD inhibitors would 
work on the post-transcriptional level, we will focus on 
the expression of PAD enzymes. PAD2 and PAD4 expres-
sion has been demonstrated in rheumatoid synovium 
[44] and synovial ﬂ  uid cells [45] and extracellularly in 
synovial ﬂ  uid [46]. PAD4 diﬀ  ers from other PAD isotypes 
in its capacity to undergo nuclear translocation due to 
the presence of a nuclear localization sequence and this 
translocation has been shown to be induced by tumor 
necrosis factor-alpha in murine and human oligo  dendro-
glial cell lines [47]. PAD expression in the synovial tissue 
is not speciﬁ  c to RA. It occurs in a variety of inﬂ  amma-
tory synovitides [41] and diseases such as inﬂ  ammatory 
bowel disease, polymyositis, and interstitial pneumonia 
[48]. While PAD2 is expressed in the synovia of both 
patients with inﬂ   ammatory arthritis and osteoarthritis 
(OA), PAD4 is predominantly expressed in the synovia of 
patients with inﬂ  ammatory arthritides rather than OA 
[44]. Th  e converse was observed in the extracellular 
compartment, where Kinloch and colleagues [46] showed 
the presence of PAD4 in the synovial ﬂ  uid of patients 
with RA, spondyloathropathies, and OA, while PAD2 
expression was found in both groups of patients with 
inﬂ  ammatory arthritis but was notably absent in those 
with OA. PAD2 and PAD4 expression in the synovium 
correlates with inﬂ   ammatory cell inﬁ  ltration,  synovial 
lining thickness, and vascularity of the deep synovium 
[44]. Foulquier and colleagues [44] demonstrated PAD2 
and PAD4 in close proximity to citrullinated ﬁ  brin 
deposits, although simultaneous detection of the two 
enzymes in the same area was rare.
Bacterial peptidylarginine deiminase
P. gingivalis, considered a primary pathogen in chronic 
periodontitis, is a Gram-negative, non-motile anaerobic 
bacterium that is the only prokaryote described to date to 
express a functional endogenous PAD enzyme [4]. To 
date, investigations of bacterial deiminases have focused 
mainly on enzymes that use free, non-peptidyl arginine 
or arginine derivatives such as arginine deiminase (ADI). 
ADIs are enzymes that catalyze the deimination of free 
arginine to citrulline, releasing ammonia. Th  ey are key 
enzymes in the widespread anaerobic pathway of arginine 
degradation and many pathogenic microorganisms use 
this pathway for energy production. Since ADIs are 
missing in higher eukaryotes, the enzyme constitutes a 
potential anti-parasitic and anti-bacterial drug target 
[49]. Th  e other group of structurally and functionally 
related enzymes produced by most bacterial species 
consists of agmatine deiminases (agmatine iminohydro-
lases, or AIHs). AIHs deiminate agmatine (a decarboxy-
lation product of arginine) to N-carbamoylputrescine   
and ammonia.
On the amino acid sequence level, PPAD shows no 
relation to eukaryotic PAD; instead, position-speciﬁ  c 
iterative-basic local alignment search tool (PSI-BLAST) 
search connects PPAD to the AIH family (Figure 2). 
Although the molecular structure of PPAD is unknown, 
its sequence similarity to AIHs with conservation of key 
catalytic and guanidino-binding residues indicates that 
the catalytic domain shares the common α/β-propeller 
fold of the guanidine-group modifying enzyme (GME) 
superfamily, which includes human PADs, microbial 
ADI, aminotransferases, dimethylarginine dimethyl-
amino  hydrolases, and AIH [50]. Of note, the database 
annotation of AIH is confusing since these enzymes are 
often referred to as ‘Porphyromonas-type peptidyl-argi-
nine deiminases’ although they most likely do not possess 
PPAD activity. Th   e three-dimensional structure of PPAD 
was predicted to consist of the amino-terminal catalytic 
α/β-propeller domain, followed by an immunoglobulin-
like β sandwich. In comparison, the published structure 
of human PAD4 is composed of two amino-terminal 
immunoglobulin-like β sandwich domains, followed by 
the catalytic α/β-propeller domain [51].
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both free arginine and peptidylarginine ([4] and our own 
unpublished observations) and preferentially targets 
carboxy-terminal arginine, although internal citrulli-
nation cannot be excluded. Furthermore, deimination by 
human PAD is calcium-dependent in contrast to that by 
PPAD, which does not appear to require any speciﬁ  c 
cofactors ([4,52] and our own unpublished observations). 
P. gingivalis has been shown, however, to increase intra-
cellular calcium concentrations by cleavage of proteinase-
activated receptor 2 (PAR 2), a G protein-coupled 
receptor found on the neutrophil surface, which may in 
turn promote human PAD activation [53].
Th  e physiological role of PPAD is unclear. It was 
suggested that production of ammonia during deimina  tion 
enhances the survival of P. gingivalis within the periodontal 
pocket [4]. Indeed, ADI- and AIH-catalyzed ammonium 
production among bacterial species is known to act as a 
virulence factor, promoting the survival of microbial 
pathogens in the host environment. Ammonia neutralizes 
acidic en  viron  ments and thereby optimizes gingipain and 
PPAD function, inactivates hemagglutinins, promotes ATP 
produc  tion, and has negative eﬀ  ects on neutrophil func-
tion [4,54]. Furthermore, it can be speculated that PPAD 
acts as a virulence factor by generating citrullinated 
peptides, which may assist the bacterium in spreading and 
circumventing the humoral immune response. However, 
the requirements for citrullination by PPAD have not been 
well investigated to date and it is unknown whether the 
citrullinated peptides are immunogenic.
Th   us, we conclude that PPAD may be more relevant to 
the initiation of autoimmunity at a site distant from the 
joint, such as the gingiva, and that PAD2 and PAD4 are 
important in generating autoantigens that perpetuate 
autoimmunity in RA once tolerance is breached. Further 
work is required to identify the regulation and substrate 
speciﬁ  city of each enzyme in order to establish a more 
precise role in the autoimmune response.
Figure 2. Alignment of amino acid sequence of catalytic domains of Porphyromonas gingivalis PAD (PPAD) (residues 86 to 363), AIH from 
Dyadobacter fermentans DSM 18053 (locus Dfer_2630, residues 60 to 352), and human PAD4 (residues 306 to 556). Residues identical in 
PPAD and AIH and/or PAD4 are highlighted. Guanidino-binding (#) and catalytic residues (*) that are conserved in all families of guanidino-group 
modifying enzyme superfamily are indicated. The amino-terminal sequence of each enzyme is unique. In PAD4, the amino-terminal portion is 
folded into two consecutive immunoglobulin-like β-sandwich domains preceding the catalytic domain harboring the α/β-propeller fold [51]. A 
long 200-residue carboxy-terminal extension of PPAD is predicted to adopt an immunoglobulin-like β-sandwich structure [50]. AIH, agmatine 
iminohydrolase; PAD, peptidylarginine deiminase.
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in rheumatoid arthritis
Although PAD4 has been most extensively studied as a 
potential therapeutic target in RA (mainly based on the 
availability of a crystal structure [51]), PAD2 may also be 
important. It is proposed that selective inhibition of PAD 
would reduce the levels of citrullinated proteins and 
consequently suppress the humoral immune response 
directed to citrullinated antigens in RA. Because PAD4 
has an important physiological role in regulating gene 
expression and PAD4 translocates into the nucleus from 
the cytosol, potential inhibitors may need to be selective 
for the extracellular compartment or other PAD isotypes 
to avoid unwanted eﬀ  ects on gene transcription. It is, 
however, not known whether intracellular or extracellular 
PAD is important in the pathophysiology of RA.
Paclitaxel is a chemotherapeutic agent that was initially 
derived from the bark of the Paciﬁ  c yew tree. It inhibits 
angiogenesis by interfering with microtubule function in 
cell mitosis, migration, chemotaxis, and intracellular 
transport [55]. In addition, in the millimolar range (half-
maximal inhibitory concentration [IC50] = approximately 
5  mM), paclitaxel inhibits PAD isolated from bovine 
brain [56]. It has been shown to prevent the induction of 
collagen-induced arthritis (CIA) and cause signiﬁ  cant 
regression of existing CIA [57]. An open-label multi-
center phase II study of paclitaxel in patients with RA 
was completed in July 2008, although results of this are 
still pending [58].
Other PAD inhibitors include F-amidine [N-α-benzoyl-
N5-(2-ﬂ  uoro-1-iminoethyl)-l-ornithine amide], Cl-amidine 
[N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-l-ornithine 
amide], and 2-chloroacetamidine, of which Cl-amidine 
was reported to be the most potent (IC50 = 5.9 μM) [59]. 
Ex vivo studies with F-amidine and Cl-amidine, using a 
cell line and an assay measuring PAD4-mediated citrulli-
nation of a nuclear protein and the resulting enhance-
ment in binding to another protein, indicated that these 
inhibitors are bioavailable [59,60]. F-amidine irreversibly 
inhibits PAD4 via the speciﬁ  c modiﬁ  cation of Cys 645, an 
active-site residue that is critical for enzyme catalysis. 
Cys 645 acts as a nucleophile to form a thiouronium 
intermediate that is hydrolyzed to form citrulline. Cl-
amidine and 2-chloroacetamidine are thought to act via a 
similar mechanism [59,61]. Inactivation by F-amidine 
and Cl-amidine is calcium-dependent [60]. In vitro 
studies with PAD4 have shown that calcium binding 
leads to a conformational change that moves Cys 645 and 
His 471 into positions that are competent for catalysis 
[51] and presumably reactive with F-amidine and Cl-
amidine. Th   is is of therapeutic importance as these com-
pounds would therefore be expected to inhibit PAD4 in 
its activated state only at sites of inﬂ  ammatory activity 
such as the synovium and not the inactive enzyme at 
other sites in the body, limiting toxicity [59]. Willis and 
colleagues [62] recently showed that Cl-amidine treat-
ment in CIA is able to inhibit clinical disease activity 
scores by 55%, 53%, and 42% in the 50, 10, and 1 mg/kg 
per day groups, respectively. Histological severity scores 
and complement C3 deposition scores paralleled the 
decreases in disease activity. In addition, mice receiving 
Cl-amidine showed reduced epitope spreading by peptide 
microarray, especially to citrullinated joint antigens. 
Interestingly, there were no changes in the percentages of 
T-cell, B-cell, or monocyte populations in treated mice 
compared with controls [62]. Th  ese results suggest that 
Cl-amidine may represent a novel class of RA thera-
peutics that speciﬁ  cally target citrullination.
Bhattacharya and colleagues [63]  demonstrated that 
human astrocytes subject to pressure showed elevated 
PAD2 levels, increased intracellular calcium concentra-
tions, and increased citrullination. Treatment with the 
cell-permeable calcium chelating agent BAPTA-AM 
(1,2-bis-(o-Aminophenoxy)-ethane-N,N,N’,N’-tetra acetic 
acid tetraacetoxymethyl ester) resulted in decreased 
intra  cellular calcium concentration and PAD2 levels. 
Th   ese results suggest that calcium modulation may be an 
alternative therapeutic strategy in modulating PAD 
activity and citrullination, although we would argue that 
this mechanism is too broad to be applicable in practice.
On the basis of the therapeutic use of tetracyclines in 
RA [23], Knuckley and colleagues [28] screened tetra-
cycline derivatives (minocycline, doxycycline, tetracy-
cline, and chlortetracycline) for their potential to inhibit 
PAD4 activity. Chlortetracycline was identiﬁ   ed as the 
most potent inhibitor (IC50 = 100 μM) and was suggested 
to bind to a region distal from the active site [28]. 
Streptomycin, an aminoglycoside antibiotic, was also 
tested because of its two guanidinium groups that could 
act as inhibitors of PAD4. Streptomycin was found to 
inhibit PAD4, though with a lower potency (IC50 = 
approximately 1.8 mM), and was suggested to bind within 
or in close proximity to the active site. Th   e data suggest 
that these compounds could provide a valuable scaﬀ  old 
for engineering inhibitors with greater potency and 
selectivity.
Porphyromonas gingivalis peptidylarginine 
deiminase as a target for treatment in rheumatoid 
arthritis
Th  e unique nature of PPAD in terms of its diﬀ  erent 
amino acid sequence, cofactor requirement, and domain 
organization compared with human PADs (Figure 2), 
along with its location on the bacterial cell surface [4], 
would make this enzyme a potential target in the 
treatment of RA provided that its possible involvement in 
disease etiology or pathology is substantiated in future 
studies. Development of therapeutics targeting PPAD is 
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of inhibitors against parasite-derived ADI with potentials 
to be used as anti-parasitic agents [64]. Since ADI, PADs, 
and PPAD are likely to use the same catalytic machinery 
to deiminate (peptidyl)arginine (Figure 2), a similar 
chemistry may be applied to develop PPAD inhibitors. 
Th  e calcium-independent deimination of carboxy-ter-
minal arginine residues speciﬁ  c to PPAD can be explored 
to develop highly selective compounds with little or no 
cross-reactivity with host enzymes.
McGraw and colleagues [4] reported that native PPAD, 
puriﬁ   ed from the bacterial culture supernatant, was 
missing the N-terminus inferred from the DNA sequence 
because of proteolysis at the Arg43-Ala44 peptide bond. 
Th  is might have been an artifact caused by the potent 
proteases, arginine-gingipains, which co-puriﬁ  ed  with 
PAD at the initial stages of protein puriﬁ  cation, or might 
have true biological signiﬁ   cance (for example, arising 
during export of the enzyme from the cell to form the 
mature protein). A recent paper on PPAD reported that 
the full-length, uncleaved form was unstable and had 
only 40% activity when compared with the truncated 
form of the enzyme [52]. Future studies aimed at 
identifying the mature, in vivo form of PPAD and its 
enzymology are required in order to pin down the 
biologically relevant form of the enzyme and as such the 
more appropriate target for therapeutic blockade.
As the PPAD enzyme is not well studied, there are no 
published studies on possible therapeutic inhibitors. To 
gain insight into the catalytic mode of PPAD, McGraw 
and colleagues [4] tested various compounds that might 
interfere with the catalytic cysteine residue (Cys 351) or 
substrate binding. Th  ey reported that the serine- and 
cysteine-protease inhibitor leupeptin is able to com-
pletely inhibit PPAD at millimolar levels (5 mM), with 
other inhibitors such as thiourea, thio-l-citrulline, and 
the serine- and cysteine-protease inhibitor TLCK (N-
alpha-p-tosyl-l-lysine chloromethyl ketone) being inhi  bi-
tory at higher concentrations (12.5 to 50 mM) [4]. Apart 
from the relatively low inhibitory potency, these 
compounds are either toxic (thiourea) or unselective 
(thio-l-citrulline is a potent inhibitor of nitric oxide 
synthase) [65] but nonetheless provide a basis for the 
development of more potent, speciﬁ  c inhibitors.
Conclusions
We have summarized a possible role for PPAD in 
breaking tolerance to citrullinated proteins, with human 
PAD2 or PAD4 or both maintaining the generation of 
citrullinated antigens in the joint. However, the evidence 
remains speculative and clearly requires further investi-
gation of the mechanisms of activity of the enzymes 
involved and how the apparently unique PAD encoded by 
P. gingivalis could generate immunogenic peptides. If 
these hypotheses are further substantiated, PAD blockade 
has the potential to switch oﬀ   auto  immunity at the point 
of initiation and inhibit the maintenance of the pathology 
in RA. Th  us, inhibition of bacterial and human PADs 
could become the ﬁ  rst treatment targeting the generation 
of the actual antigens that drive the disease.
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